Literature DB >> 26229727

Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.

Cody P Coyne1, Toni Jones1, Andrzej Sygula2, John Bailey3, Lesya Pinchuk1.   

Abstract

PURPOSE: Discover the anti-neoplastic efficacy of epirubicin-(C13-imino)-[anti-HER2/neu] against chemotherapeutic-resistant SKBr-3 mammary carcinoma and delineate the capacity of selenium to enhance it's cytotoxic anti-neoplastic potency.
METHODS: In molar excess, EMCH was combined with epirubicin to create a covalent epirubicin-(C13-imino)-EMCH-maleimide intermediate with sulfhydryl-reactive properties. Monoclonal immunoglobulin selective for HER2/neu was then thiolated with 2-iminothiolane at the terminal ε-amine group of lysine residues. The sulfhydryl-reactive epirubicin-(C13-imino)-EMCH intermediate was then combined with thiolated anti-HER2/neu monoclonal immunoglobulin. Western-blot analysis was utilized to characterize the molecular weight profiles while binding of epirubicin-(C13-imino)-[anti-HER2/neu] to membrane receptors was determined by cell-ELISA utilizing populations of SKBr-3 mammary carcinoma that highly over-expresses HER2/neu complexes. Anti-neoplastic potency of epirubicin-(C13-imino)-[anti-HER2/neu] between the epirubicin-equivalent concentrations of 10-12 M and 10-7 M was determined by vitality staining analysis with and without the presence of selenium (5 μM).
RESULTS: Epiribucin-(C13-imino)-[anti-HER2/neu] between epirubicin-equivalent concentrations of 10-8 M to 10-7 M consistently evoked higher anti-neoplastic potency than "free" non-conjugated epirubicin which corresponded with previous investigations utilizing epirubicin-(C3-amide)-[anti-HER2/neu] and epirubicin-(C3-amide)-[anti-EGFR]. Selenium at 5 mM consistently enhanced the cytotoxic anti-neoplastic potency of epirubicin-(C13-imino)-[anti-HER2/neu] at epirubicin equivalent concentrations (10-12 to 10-7 M).
CONCLUSIONS: Epirubicin-(C13-imino)-[anti-HER2/neu] is more potent than epirubicin against chemotherapeutic-resistant SKBr-3 mammary carcinoma and selenium enhances epirubicin-(C13-imino)-[anti-HER2/neu] potency. The methodology applied for synthesizing epirubicin-(C13-imino)-[anti-HER2/neu] is relatively time convenient and has low instrumentation requirements.

Entities:  

Keywords:  Chemotherapeutic-Resistant Mammary Carcinoma; Epirubicin-(C13-Imino)-[Anti-HER2/neu]; HER2/neu; Selenium; Synthesis

Year:  2011        PMID： 26229727      PMCID： PMC4517615          DOI： 10.4236/jct.2011.21004

Source DB:  PubMed          Journal:  J Cancer Ther        ISSN： 2151-1934


  88 in total

1.  Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.

Authors:  Felix Kratz; André Warnecke; Karin Scheuermann; Cornelia Stockmar; Jürgen Schwab; Peter Lazar; Peter Drückes; Norbert Esser; Joachim Drevs; Didier Rognan; Caterina Bissantz; Caterina Hinderling; Gerd Folkers; Iduna Fichtner; Clemens Unger
Journal:  J Med Chem       Date:  2002-12-05       Impact factor: 7.446

2.  The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage.

Authors:  Dirk Lebrecht; Andrea Geist; Uwe-Peter Ketelsen; Jörg Haberstroh; Bernhard Setzer; Felix Kratz; Ulrich A Walker
Journal:  Int J Cancer       Date:  2007-02-15       Impact factor: 7.396

3.  Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation.

Authors:  K Ulbrich; T Etrych; P Chytil; M Jelínková; B Ríhová
Journal:  J Drug Target       Date:  2004       Impact factor: 5.121

4.  Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates.

Authors:  R O Dillman; D E Johnson; J Ogden; D Beidler
Journal:  Mol Biother       Date:  1989

5.  Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.

Authors:  Shousong Cao; Farukh A Durrani; Youcef M Rustum
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

6.  Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.

Authors:  P A Trail; D Willner; S J Lasch; A J Henderson; S Hofstead; A M Casazza; R A Firestone; I Hellström; K E Hellström
Journal:  Science       Date:  1993-07-09       Impact factor: 47.728

7.  The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?

Authors:  Wageh M Awara; Alaa E El-Sisi; Magda E El-Sayad; Ahmed E Goda
Journal:  Pharmacol Res       Date:  2004-11       Impact factor: 7.658

8.  In vitro study on the individual and synergistic cytotoxicity of adriamycin and selenium nanoparticles against Bel7402 cells with a quartz crystal microbalance.

Authors:  Liang Tan; Xue'en Jia; Xiangfu Jiang; Youyu Zhang; Hao Tang; Shouzhuo Yao; Qingji Xie
Journal:  Biosens Bioelectron       Date:  2008-11-14       Impact factor: 10.618

9.  Anthracycline-based combined chemotherapy in the mouse model.

Authors:  M Popovic; J Kolarovic; M Mikov; S Trivic; B Kaurinovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Apr-Jun       Impact factor: 2.441

10.  Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro.

Authors:  A Lau; G Bérubé; C H Ford; M Gallant
Journal:  Bioorg Med Chem       Date:  1995-10       Impact factor: 3.641
View more
  9 in total

1.  Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549).

Authors:  C P Coyne; Lakshmi Narayanan
Journal:  J Pharm Drug Deliv Res       Date:  2015-03-20

2.  Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Clin Exp Oncol       Date:  2013

3.  Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  Cancer Clin Oncol       Date:  2012-11

4.  Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.

Authors:  Cody P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Ther       Date:  2012-10

5.  Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Ther       Date:  2015-01

6.  Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Res Ther Oncol       Date:  2014-04-09

7.  Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  Med Chem (Los Angeles)       Date:  2013-05

8.  Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549).

Authors:  Cody P Coyne; Lakshmi Narayanan
Journal:  Drug Des Devel Ther       Date:  2016-08-12       Impact factor: 4.162

9.  Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549).

Authors:  Cody P Coyne; Lakshmi Narayanan
Journal:  Chem Biol Drug Des       Date:  2016-12-20       Impact factor: 2.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.